Doxorubicin Market Analysis

  • Report ID: 4876
  • Published Date: Oct 14, 2024
  • Report Format: PDF, PPT

Doxorubicin Market Analysis

Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

The global doxorubicin market is segmented and analyzed for demand and supply by distribution channel into hospital pharmacy, retail pharmacy, and online pharmacy. Out of these, the hospital pharmacy segment is estimated to gain the largest market share of about 41% in the year 2037. The growth of the segment can be attributed to the increasing demand for hospital services and the availability of cost-effective drugs. The rising number of private hospitals, which are equipped with advanced technology and well-trained healthcare professionals, is also driving the growth of this segment. It was observed that currently, India is home to more than 43,480 private hospitals. As of 2020, France was home to 670 private not-for-profit hospitals and 970 private for-profit hospitals, while the United States had over 1574 private for-profit hospitals. Additionally, the availability of generic drugs, which are more affordable than brand-name drugs, is also contributing to the increased demand for hospital pharmacy products.

Drug Formulation (Lyophilized Powder, Injection)

The global market is segmented and analyzed for demand and supply by drug formulation into lyophilized powder and doxorubicin injection. Out of these, the doxorubicin injection segment is estimated to gain a significant market share of about 67% in the year 2037. The growth of the segment can be attributed to the increasing prevalence of cancer and other life-threatening diseases, combined with the growing demand for doxorubicin injections as a primary treatment for cancer. Additionally, the availability of various forms of doxorubicin injections, such as liposomal and hybrid formulations, is also contributing to the growth of the segment. Moreover, the rising demand for improved treatment outcomes and the emergence of targeted cancer therapies with doxorubicin injections have further increased the demand for doxorubicin injections.

Our in-depth analysis of the global market includes the following segments:

     By Drug Formulation

  • Lyophilized Powder
  • Doxorubicin Injection

     By Application

 

  • Bladder Cancer
  • Kaposi Sarcoma
  • Leukemia
  • Lymphoma
  • Breast Cancer
  • Ovarian Cancer
  • Multiple Myeloma
  • Kidney cancer
  • Others

     By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
 
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4876
  • Published Date: Oct 14, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of doxorubicin is assessed at USD 1.07 billion.

The doxorubicin market size was valued at USD 1.01 billion in 2024 and is set to reach USD 2.24 billion by the end of 2037, expanding at around 6.9% CAGR during the forecast period i.e., between 2025-2037. Increasing prevalence of cancer and rising demand for targeted therapies will boost the market growth.

North America industry is projected to have the highest growth till 2037, owing to increasing investments in research and development for new treatments for breast cancer in the region.

The major players in the market include Pfizer Inc., Johnson and Johnson, Zydus Group, Cipla Limited, Sun Pharmaceutical Industries Ltd, Padagis, Reddy Laboratories Ltd., Cadila Healthcare Limited, Novartis International AG, MicroBiopharm Japan Co. Ltd, .
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample